The effect of botulinum toxin type A injections on production of sebum in seborrhea
Year: 2018, volume 14 Issue: №4 Pages: 740-744
Heading: Dermatovenerology Article type: Original article
Authors: Kondrateva А.А., Galkina Е.М., Karakaeva A.V., Morrison A.V., Morrison V.V.
Organization: Saratov State Medical University
Heading: Dermatovenerology Article type: Original article
Authors: Kondrateva А.А., Galkina Е.М., Karakaeva A.V., Morrison A.V., Morrison V.V.
Organization: Saratov State Medical University
Summary:
Aim: assessment of sebum production dynamics in patients who received treatment for mimic and static wrinkles in glabella and forehead regions with phase of a menstrual cycle taken into account. Material and Methods. We observed 15 female patients aged 24-38 years who received botulinum toxin therapy. Each BTX-Avial contained 100 units of lyophilized preparation. The solution of BTX-Awas prepared by mixing it with 2 ml of sterile saline. Five intramuscular injections with 2 U of BTX-A per point were made across the forehead, while 3 U injections were done in the glabellar area. The total amount of botulinum toxin used was 19 U per patient. Results. Maximum decrease in sebum production was observed 4 weeks after botulinum toxin injections, and return to baseline was observed at 16 weeks of follow-up. Conclusion. According to the obtained data, it may be stated that botulinum toxin injections affect sebum production with a maximum decrease observed at 4 weeks after botulinum toxin therapy.
Bibliography:
1 Bagherani N, Smoller B. The efficacy of botulinum toxin type A in the treatment of Hailey-Hailey disease. Dermatol Ther 2016; 29 (6): 6-7
2 Bessa GR, Grazziotin TC, Manzoni AP, et al. Hailey-Hailey disease treatment with botulinum toxin type A. An Bras Dermatol 2010;85:717-22
3 Engin B, Kutlubay Z, Qelik U, et al. Hailey-Hailey disease: a fold (intertriginous) dermatosis. Clin Dermatol 2015; 33: 452-5
4 Lowe NJ, Campanati A, Bodokh I, et al. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol 2004; 151: 1115-22
5 Campanati A, Giuliodori K, Martina E, etal. Onabotulinum-toxin type A (Botox) versus incobotulinumtoxin type A(Xeomin) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial J Neural Transm 2014; 121:21-6
6 Yan AC, Aasi SZ, Alms WJ, et al. Aquagenic palmoplantar keratoderma. J Am Acad Dermatol 2001; 44: 696-9
7 Diba VC, Cormack GC, Burrows NP. Botulinum toxin is helpful in aquagenic palmoplantar keratoderma. Br J Dermatol 2005; 152:394-5
8 Picardo M, Ottaviani M, Camera E. Sebaceous gland lip-ids. Dermatoendocrinol 2009; 1: 68-71
9 Camera E, Ludovici M, Galante M, et al. Comprehensive analysis of the major lipid classes in sebum by rapid resolution high performance liquid chromatography and electrospray mass spectrometry. J Lipid Res 2010; 51: 3377- 88
10 Kim BY, Choi JW, Park КС, Youn SW. Sebum, acne, skin elasticity, and gender difference- which is the major influencing factor for facial pores? Skin Res Technol 2013; 19: E45-53
11 Chen W, Zouboulis CC. Hormones and the piloseba-ceous unit. Dermatoendocrinol 2009; 1: 81-6
12 Rosenfield RL, Deplewski D, KentsisA, Ciletti N. Mechanisms of androgen induction of sebocyte differentiation. Dermatology 1998; 196(1): 43-6
13 Man MQ, Xin SJ, Song SP, et al. Variations of skin surface pH, sebum content, andstratumcorneum hydration with age and gender in a large Chinese population. Skin Pharmacol Physi-ol 2009; 22: 190-9
14 Wan MJ, SuXY, Zheng Y, etal. Seasonal variability in the biophysical properties of forehead skin in women in Guangzhou City, China. Int J Dermatol 2015; 54: 1319-24
15 Roh M, Han M, Kim D, Chung К Sebum output as a factor contributing to the size of facial pores. Br J Dermatol 2006; 155:890-4
16 Sugiyama-Nakagiri Y, Sugata K, Hachiya A, et al. Ethnic differences in the structural properties of facial skin. J Dermatol Sci2009;53: 135-9
17 Pierard-Franchimont C, Pierard GE, Kligman A. Rhythm of sebum excretion during the menstrual cycle. Dermatology (Basel) 1991; 182: 211-3
18 Pierard GE, Pierard-Franchimont С The sebutape technique as an aid for monitoring androgen-dependent disorders. EurJMed 1992; 1: 109-12
19 Martignoni E, Godi L, Pacchetti C, et al. Is seborrhea a sign of autonomic impairment in Parkinson's disease? J Neural-Transm 1997; 104: 1295-304
20 Slesarenko NA, Bakulev AL, Shabogina AA, et al. Side effects of systemic retinoid therapy in patients with severe psoriasis. Saratov Journal of Medical Scientific Research 2013; 9 (3): 549-52
21 Bakulev AL, Kravchenya SS, Platonova AN, Igonina IA. Long-term therapy of severe acne: selection of doses and administration schemes for systemic isotretinoin. Vestnik der-matologii i venerologii 2014; (1): 81-8
22 Shah AR. Use of intradermal botulinum toxin to reduce sebum production and facial pore size. J DrugsDermatol 2008; 7: 847-50
23 RoseAE, Goldberg DJ. Safety and efficacy of intradermal injection of botulinum toxin for the treatment of oily skin. Dermatol Surg 2013; 39 (pt 1): 443-8
24 Kim YS, Hong ES, Kim HS. Botulinum toxin in the field of dermatology: Novel indications. Toxins 2017; 9: 403
25 Li ZJ, Park SB, Sohn КС, et al. Regulation of lipid production by acetylcholine signaling in human sebaceous glands. J Dermatol Sci 2013; 72: 116-22
26 Thiboutot D, Harris G, lies V, et al. Activity of the type 1-5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol 1995; 105: 209-14.
27 Bulstrode NW, Grobbelaar АО. Long-term prospective follow-up of botulinum toxin treatment for facial rhytides. Aesthet Plast Surg 2002; 265: 356-9.
28 Min P, Xi W, Grassetti L, et al. Sebum production alteration after botulinum toxin type A injections for the treatment of forehead rhytides: A prospective randomized double-blind dose-comparative clinical investigation. Aesthet Surg J 2015; 35: 600-10
29 Plewig G, Kligman A. Acne and Rosacea. 3rd ed. Springer, 2000; p. 58-67.
| Attachment | Size |
|---|---|
| 2018_4-1_740-744.pdf | 353.29 KB |
Русский
English